EuroGentest

What can EuroGentest do for you?

Health professionals - find updated information on genetic tests: clinical utility gene cards

Genetic laboratories - the opportunity to join our expert working groups and to participate in QM workshops and EQA schemes

Patients, Public and Policy - find information leaflets on all aspects of genetic testing

Find all of this information and more on:

www.eurogentest.org

EuroGentest

Project Management

Katholieke Universiteit Leuven
Center for Human Genetics
Belgium

Coordinator
Professor Gert Matthijs

Project Manager
Valerie De Groote

Administrative Officer
Liliane Geyskens

Contact: admin@eurogentest.org

www.eurogentest.org

EuroGentest

Genetic Testing in Europe

SEVENTH FRAMEWORK PROGRAMME

www.eurogentest.org

EuroGentest2 is a non-profit coordination action funded by the 7th Framework of the European Commission for **the harmonization and further improvement of genetic services**, across Europe. This project builds further on the goals achieved in the previous EuroGentest NoE project.

Improving quality in genetic laboratories

EuroGentest has developed and will continue to provide support for quality management, including:

- **Interactive workshops** and training courses on ISO-accreditation.

Spreading the quality message

- European **EQA schemes** for cytogenetics (CEQA), molecular genetics (CF network and EMQN) and biochemical genetics (ERNDIM) with new pilot EQAs for the existing European EQA programs, best practice guidelines and control materials.

CEQA Cytogenetic European Quality Assessment
ERNDIM QUALITY ASSURANCE IN LABORATORY TESTING FOR IEM
CF Cystic Fibrosis European Network
EMQN The European Molecular Genetics Quality Network

Creating a consensus

- **User-friendly tools** to find information on genetic tests available in Europe, and on quality management of laboratories offering these tests, in collaboration with Orphanet.

Generating the world's most comprehensive database

orphanet

Our aim is to measurably improve the quality of the management and provision of genetic services for the benefit of the patient and to ensure that accreditation is considered the norm.

Genetic testing as part of health care

EuroGentest2 will continue to promote and coordinate the development of "**Clinical Utility Gene Cards**", which aim at creating and updating evaluations of individual genetic tests focusing on their utility in clinical work, and spreading them efficiently for the use of clinicians in Europe and elsewhere. They are freely available from the European Journal of Human Genetics.

EuroGentest has also created the **patient leaflets**, which contain general information on genetic testing in a comprehensive way for patients and their family in more than 27 languages.

Building on the **guidelines** for genetic **counselling** that were prepared previously, **EuroGentest2** will expand the work in the direction of pre-implantation genetic testing (PGD) and non-invasive prenatal testing (NIPD).



Members of EuroGentest2 are concerned about **direct to consumer testing** (DTC) and would like to contribute to the development of guidelines and rules for such commercial activities.

Also, EuroGentest2 wants to find models and create guidelines on how to **define the specific role of and to optimize interaction between different professionals**, particularly clinical geneticists and non-genetic specialists, especially in the context of new emerging technologies, to offer patients and their families the best possible service.

EuroGentest

Evaluating new technologies

EuroGentest has supported the **validation** of existing tests and guided the implementation of **new technologies** into diagnostic application, including methods for NIPD.

Several validation reports have been prepared. More importantly, a **framework to guide the laboratories through validation has been prepared (Mattocks *et al.*, European Journal of Human Genetics (2010))**.



Several workshops are given and guidelines are in preparation on the implementation of new technologies such as **Next Generation Sequencing** into diagnostics.